Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of AD101 ointment in adults with mild to moderate atopic dermatitis
CTR20263748Phase 2Active
- Sponsor
- 01Life Institute
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing AD101 ointment with Placebo ointment (2 arms). Primary endpoints: Percent change from baseline in Eczema Area and Severity Index and Pharmacokinetic parameters of AD101 and metabolites. Started Sep 2026; status: active.
02
Drugs
Ismidenon
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20263748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263748.